



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov



CONFIRMATION NO. 6984

Bib Data Sheet

| | | | | |
|--|---|--|---|--|
| SERIAL NUMBER 09/403,213 | FILING OR 371(c) DATE 06/22/2000 RULE | CLASS 514 | GROUP ART UNIT 1635 | ATTORNEY DOCKET NO. LEBV.004.01U |
| APPLICANTS Matheus Hubertus Maria Noteborn, Leiden, NETHERLANDS; Alexandra Maria Pietersen, Leiden, NETHERLANDS; | | | | |
| ** CONTINUING DATA ***** This application is a CIP of 09/740,676 12/18/2000 ABN which is a CIP of 08/482,161 06/07/1995 PAT 6,162,461 which is a CIP of 08/454,121 11/30/1995 PAT 6,071,520 which is a 371 of PCT/NL94/00168 07/19/1994 which is a CIP of 08/030,335 03/08/1993 PAT 5,491,073 which is a 371 of PCT/NL91/00165 09/11/1991 | | | | |
| ** FOREIGN APPLICATIONS ***** EUROPEAN PATENT OFFICE (EPO) 97201121.7 04/15/1997 EUROPEAN PATENT OFFICE (EPO) 97203595.0 11/15/1997 | | | | |
| IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 07/07/2000 | | | | |
| Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after met Allowance Verified and Acknowledged <u> </u> Examiner's Signature <u> </u> Initials | | STATE OR COUNTRY NETHERLANDS | SHEETS DRAWING 7 | TOTAL CLAIMS 21 |
| INDEPENDENT CLAIMS 2 | | | | |
| ADDRESS 24247 | | | | |
| TITLE Gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin | | | | |
| FILING FEE RECEIVED 988 | FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following: | | <input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit | |